<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01409564</url>
  </required_header>
  <id_info>
    <org_study_id>06-2009-145</org_study_id>
    <nct_id>NCT01409564</nct_id>
  </id_info>
  <brief_title>Cilostazol Augmentation Study in Dementia</brief_title>
  <official_title>Cilostazol Augmentation Study In Dementia (CASID): A Randomized, Placebo-controlled Pilot Study to Compare the Efficacy Between Donepezil Monotherapy and Cilostazol Augmentation Therapy in Alzheimer's Disease Patients With Subcortical White Matter Hyperintensities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea OIAA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of cilostazol augmentation in mild to
      moderate Alzheimer disease patients with subcortical white matter hyperintensities (WMHI)
      treated by donepezil.

      Dementia is the most disabling disease in the old age. The prevalence of dementia is 5-10% of
      the elders. AchEIs (donepezil, galantamine, rivastigmine) are used to treat mild to moderate
      dementia, but these drugs only relate to symptomatic improvement and the response rates are
      less than 30%.

      Cilostazol is a cyclic adenosine monophosphate phosphodiesterase 3 inhibitor (PDE3I) and used
      as antiplatelet agent in subcortical vascular disease (WMHI). And it upregulates
      phosphorylation of cyclic adenosine monophosphate-pathway response element binding protein
      (CREB) which plays a crucial role in memory enhancement and synaptic plasticity related to
      neurodegeneration prevention.

      The investigators will try cilostazol augmentation in dementia patients with WMHI receiving
      donepezil to see the addictive effects of cilostazol using cognitive tasks and PET imaging.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regionally Averaged Cerebral Glucose Uptake Changes Measured by FDG PET Uptake With Voxel-based Method</measure>
    <time_frame>Baseline, 24-week</time_frame>
    <description>Regional cerebral glucose uptake level was measured as the ratio value of FDG uptake of the each unit level to the global mean uptake value.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog)</measure>
    <time_frame>Baseline, 12-week, 24-week</time_frame>
    <description>The ADAS-Cog score is measured by the number of questions answered incorrectly, therefore the higher is the worse.
Score Scale: 0-75 (min-MAX)
Each subcategory scores are summed.
Word-recall test (0-10)
Commands (0-5)
Constructional praxis (0-5)
Naming Objects/ Fingers (0-5)
Ideational Praxis (0-5)
Orientation (0-8)
Word Recognition (0-12)
Remembering Test Instructions (0-5)
Spoken Language Ability (0-5)
Word Finding Difficulty (0-5)
Comprehension (0-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examination (MMSE) in the Korean Version of the CERAD Assessment Packet)</measure>
    <time_frame>Baseline, 12-month, 24-month</time_frame>
    <description>Basic cognitive functions are checked. (0-30) The score is better when higher.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>Baseline, 12-month, 24-month</time_frame>
    <description>The caregiver answered to the questions given to measure the cognitive function level of the patients in daily living. Lower scores indicate greater severity.
23 questions Score Scale: 0-78 (min-MAX)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)</measure>
    <time_frame>Baseline, 12-month, 24-month</time_frame>
    <description>Measured by professionally trained clinicians. Higher score indicates more severe AD symptoms.
Score Scale: 0-18 (min-MAX)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fazekas Scale</measure>
    <time_frame>Baseline</time_frame>
    <description>Level of severity of white matter lesions in AD patients who can be legitimately administered with cilostazol. Measured by professionally trained clinicians.
The higher score indicates more severe white matter lesion. Max-min: 0-3</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Alzheimer's Dementia</condition>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group means dementia patients group receiving donepezil with placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.</description>
    <arm_group_label>Cilostazol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men/women over sixty years old

          -  Patients with slight and moderate dementia (MMSE score is over 10 under 26.)

          -  Patients with probable Alzheimer's disease according to the standard of NINCDS-ADRDA

          -  Patients accompanied with WMHI on Brain MRI (Fazeka's scale 1~3)

        Exclusion Criteria:

          -  Those who do not agree to the test in a written form

          -  Patients who accompany other diseases except cerebral atrophy or change of subcortical
             white matter due to Alzheimer's disease on brain MRI

          -  Patients who should not use Cilostazol (① patients with bleeding tendency ② patients
             with congestive heart failure ③ patients who have a medical history of
             hypersensitivity to this medicine or constituent of this medicine ④ those who use
             anticoagulant and clot buster)

          -  Patients who suffer from nerve diseases or mental diseases which have influence on
             cognitive function except Alzheimer's disease (for example, schizophrenia, severe
             depression, mental retardation and etc.)

          -  Patients who are suspected to have a personal history of drug addiction or alcoholism
             within recent 10 years

          -  Patients who have severe problems in eye sight or hearing so that it is impossible to
             conduct the test smoothly

          -  Patients who the researchers think are inappropriate for taking part in the test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jung-Seok Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SMG-SNU Boramae Medical Center, Seoul, Republic of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2011</study_first_submitted>
  <study_first_submitted_qc>August 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2011</study_first_posted>
  <results_first_submitted>August 19, 2013</results_first_submitted>
  <results_first_submitted_qc>April 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 13, 2014</results_first_posted>
  <last_update_submitted>April 14, 2014</last_update_submitted>
  <last_update_submitted_qc>April 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jung-Seok Choi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's dementia</keyword>
  <keyword>Cilostazol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>46 Subjects were enrolled in the single center of Seoul National University Boramae Hospital. The diagnosis of probable AD was made according to the criteria of NINCDS-ADRDA (MMSE score 10 ~ 26). Enrollment has started in July 2010 to end in March 2012.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cilostazol</title>
          <description>Cilostazol group includes dementia patients receiving donepezil with cilostazol augmentation. All the randomly assigned AD patients in cilostazol group received 10 mg of Donepezil along with 200 mg of cilostazol per a day, doubly blinded. All the medications were orally administered. For the initial two weeks, patients only received 100 mg of cilstazol per a day to minimize the instabilities. Afterwards, for 22 weeks, patients received 200 mg of cilostazol.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo group includes dementia patients receiving donepezil with placebo. All the patients were randomly assigned as placebo group and received 10 mg of Donepezil along with the same dose of sugar pill as normal cilostazol. All the clinical assessments and medications were doubly blinded. All the medications were orally administered.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>low medication compliance</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>brain abnormalities found in T1 MR</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>18 subjects for each group were enrolled in the final list.</population>
      <group_list>
        <group group_id="B1">
          <title>Cilostazol</title>
          <description>Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo group means dementia patients group receiving donepezil with placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.00" spread="6.26"/>
                    <measurement group_id="B2" value="78.05" spread="6.09"/>
                    <measurement group_id="B3" value="78.53" spread="6.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Regionally Averaged Cerebral Glucose Uptake Changes Measured by FDG PET Uptake With Voxel-based Method</title>
        <description>Regional cerebral glucose uptake level was measured as the ratio value of FDG uptake of the each unit level to the global mean uptake value.</description>
        <time_frame>Baseline, 24-week</time_frame>
        <population>Number of patients with increased whole brain glucose uptake level. In the real analysis, however, a voxel-based image analysis results were used; therefore, data which can be entered here is not much meaningful.</population>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol, Baseline</title>
            <description>Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation at the baseline.</description>
          </group>
          <group group_id="O2">
            <title>Cilostazol, 24-week</title>
            <description>Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation after 24 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Baseline</title>
            <description>Placebo group means dementia patients group receiving donepezil with placebo at the baseline.</description>
          </group>
          <group group_id="O4">
            <title>Placebo, 24-week</title>
            <description>Placebo group means dementia patients group receiving donepezil with placebo after 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Regionally Averaged Cerebral Glucose Uptake Changes Measured by FDG PET Uptake With Voxel-based Method</title>
          <description>Regional cerebral glucose uptake level was measured as the ratio value of FDG uptake of the each unit level to the global mean uptake value.</description>
          <population>Number of patients with increased whole brain glucose uptake level. In the real analysis, however, a voxel-based image analysis results were used; therefore, data which can be entered here is not much meaningful.</population>
          <units>Bq/Bq (no unit)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Left Parietal Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.70" spread="9.51"/>
                    <measurement group_id="O2" value="80.40" spread="8.27"/>
                    <measurement group_id="O3" value="84.60" spread="7.47"/>
                    <measurement group_id="O4" value="81.33" spread="6.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Parietal Lobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.03" spread="10.26"/>
                    <measurement group_id="O2" value="79.00" spread="9.55"/>
                    <measurement group_id="O3" value="85.29" spread="8.62"/>
                    <measurement group_id="O4" value="81.91" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Inferior Frontal Gyrus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.74" spread="7.03"/>
                    <measurement group_id="O2" value="86.82" spread="6.06"/>
                    <measurement group_id="O3" value="85.97" spread="5.72"/>
                    <measurement group_id="O4" value="83.12" spread="5.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Inferior Frontal Gyrus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.11" spread="6.48"/>
                    <measurement group_id="O2" value="71.39" spread="4.82"/>
                    <measurement group_id="O3" value="74.02" spread="6.38"/>
                    <measurement group_id="O4" value="71.44" spread="5.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures analysis of variance (ANOVA) was used to test group*time interaction effect in glucose uptake of Left Parietal Lobe in two groups on two data points (baseline, 24-week).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Repeated ANOVA</method>
            <method_desc>Uncorrected, Repeated ANOVA</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures analysis of variance (ANOVA) was used to test group*time interaction effect in glucose uptake of Right Parietal Lobe in two groups on two data points (baseline, 24-week).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Repeated ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures analysis of variance (ANOVA) was used to test group*time interaction effect in glucose uptake of Left Inferior Frontal Gyrus in two groups on two data points (baseline, 24-week).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Repeated ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Repeated-measures analysis of variance (ANOVA) was used to test group*time interaction effect in glucose uptake of Right Inferior Frontal Gyrus in two groups on two data points (baseline, 24-week).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Repeated ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog)</title>
        <description>The ADAS-Cog score is measured by the number of questions answered incorrectly, therefore the higher is the worse.
Score Scale: 0-75 (min-MAX)
Each subcategory scores are summed.
Word-recall test (0-10)
Commands (0-5)
Constructional praxis (0-5)
Naming Objects/ Fingers (0-5)
Ideational Praxis (0-5)
Orientation (0-8)
Word Recognition (0-12)
Remembering Test Instructions (0-5)
Spoken Language Ability (0-5)
Word Finding Difficulty (0-5)
Comprehension (0-5)</description>
        <time_frame>Baseline, 12-week, 24-week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group means dementia patients group receiving donepezil with placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-cog)</title>
          <description>The ADAS-Cog score is measured by the number of questions answered incorrectly, therefore the higher is the worse.
Score Scale: 0-75 (min-MAX)
Each subcategory scores are summed.
Word-recall test (0-10)
Commands (0-5)
Constructional praxis (0-5)
Naming Objects/ Fingers (0-5)
Ideational Praxis (0-5)
Orientation (0-8)
Word Recognition (0-12)
Remembering Test Instructions (0-5)
Spoken Language Ability (0-5)
Word Finding Difficulty (0-5)
Comprehension (0-5)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.28" spread="8.79"/>
                    <measurement group_id="O2" value="27.78" spread="7.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.33" spread="6.75"/>
                    <measurement group_id="O2" value="24.83" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.78" spread="8.19"/>
                    <measurement group_id="O2" value="24.78" spread="7.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated ANOVA, tested for group*time interaction effect of ADAS-Cog scores on three data points (Baseline, 12-week, 24-week)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <method>Repeated ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mini-Mental State Examination (MMSE) in the Korean Version of the CERAD Assessment Packet)</title>
        <description>Basic cognitive functions are checked. (0-30) The score is better when higher.</description>
        <time_frame>Baseline, 12-month, 24-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group means dementia patients group receiving donepezil with placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Mini-Mental State Examination (MMSE) in the Korean Version of the CERAD Assessment Packet)</title>
          <description>Basic cognitive functions are checked. (0-30) The score is better when higher.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.11" spread="3.61"/>
                    <measurement group_id="O2" value="15.44" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.67" spread="4.04"/>
                    <measurement group_id="O2" value="15.83" spread="4.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.39" spread="3.94"/>
                    <measurement group_id="O2" value="16.22" spread="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated ANOVA, tested for group*time interaction effect of MMSE scores on three data points (Baseline, 12-week, 24-week)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>Repeated ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activities of Daily Living (ADCS-ADL)</title>
        <description>The caregiver answered to the questions given to measure the cognitive function level of the patients in daily living. Lower scores indicate greater severity.
23 questions Score Scale: 0-78 (min-MAX)</description>
        <time_frame>Baseline, 12-month, 24-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group means dementia patients group receiving donepezil with placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Activities of Daily Living (ADCS-ADL)</title>
          <description>The caregiver answered to the questions given to measure the cognitive function level of the patients in daily living. Lower scores indicate greater severity.
23 questions Score Scale: 0-78 (min-MAX)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.17" spread="11.61"/>
                    <measurement group_id="O2" value="53.56" spread="14.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.00" spread="13.14"/>
                    <measurement group_id="O2" value="49.33" spread="17.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.33" spread="15.88"/>
                    <measurement group_id="O2" value="51.17" spread="16.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated ANOVA, tested for group*time interaction effect of ADCS-ADL scores on three data points (Baseline, 12-week, 24-week)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Repeated ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)</title>
        <description>Measured by professionally trained clinicians. Higher score indicates more severe AD symptoms.
Score Scale: 0-18 (min-MAX)</description>
        <time_frame>Baseline, 12-month, 24-month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group means dementia patients group receiving donepezil with placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)</title>
          <description>Measured by professionally trained clinicians. Higher score indicates more severe AD symptoms.
Score Scale: 0-18 (min-MAX)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" spread="2.30"/>
                    <measurement group_id="O2" value="4.72" spread="1.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.42" spread="2.05"/>
                    <measurement group_id="O2" value="5.28" spread="2.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-week</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.44" spread="2.49"/>
                    <measurement group_id="O2" value="5.33" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Repeated ANOVA, tested for group*time interaction effect of Summed CDR scores on three data points (Baseline, 12-week, 24-week)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fazekas Scale</title>
        <description>Level of severity of white matter lesions in AD patients who can be legitimately administered with cilostazol. Measured by professionally trained clinicians.
The higher score indicates more severe white matter lesion. Max-min: 0-3</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cilostazol</title>
            <description>Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group means dementia patients group receiving donepezil with placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Fazekas Scale</title>
          <description>Level of severity of white matter lesions in AD patients who can be legitimately administered with cilostazol. Measured by professionally trained clinicians.
The higher score indicates more severe white matter lesion. Max-min: 0-3</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of Patients Scored 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Patients Scored 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of Patients Scored 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Distribution of Fazekas scale in two groups according to Chi-square test results.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Cilostazol</title>
          <description>Cilostazol group means dementia patients group receiving donepezil with cilostazol augmentation.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo group means dementia patients group receiving donepezil with placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea, Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Jung Seok Choi</name_or_title>
      <organization>Seoul National University Hospital</organization>
      <phone>82-2-870-3461</phone>
      <email>choijs@neuroimage.snu.ac.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

